Viking Therapeutics, Inc. - COMMON STOCK (VKTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q2 2015 to Q4 2025

Type / Class
Equity / COMMON STOCK
Symbol
VKTX on Nasdaq
Shares outstanding
113,177,462
Price per share
$30.24
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
71,839,104
Total reported value
$2,527,302,429
% of total 13F portfolios
0.01%
Share change
-931,968
Value change
-$4,915,384
Number of holders
413
Price from insider filings
$30.24
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 5.1% -40% $151,689,488 -$105,010,859 5,772,051 -41% FMR LLC 30 Sep 2025
BlackRock, Inc. 4.5% -16% $140,580,417 -$23,501,200 5,031,511 -14% BlackRock, Inc. 31 Mar 2025

As of 31 Dec 2025, 413 institutional investors reported holding 71,839,104 shares of Viking Therapeutics, Inc. - COMMON STOCK (VKTX). This represents 63% of the company’s total 113,177,462 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) together control 47% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.8% 9,984,487 -0.15% 0.01% $351,254,252
BlackRock, Inc. 5.8% 6,611,874 +18% 0% $232,605,730
FMR LLC 5.8% 6,557,766 +13% 0.01% $230,702,223
STATE STREET CORP 3.9% 4,445,430 -1.5% 0.01% $156,390,227
MORGAN STANLEY 2.7% 3,076,270 -18% 0.01% $108,223,187
TWO SIGMA INVESTMENTS, LP 2.2% 2,435,737 +17% 0.13% $85,689,228
TWO SIGMA ADVISERS, LP 1.9% 2,129,228 +37% 0.15% $74,906,241
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,994,509 +24% 0% $70,182,515
CITADEL ADVISORS LLC 1.5% 1,732,421 -8.7% 0.04% $60,946,570
D. E. Shaw & Co., Inc. 1.5% 1,718,493 +965% 0.05% $60,456,584
JANE STREET GROUP, LLC 1.3% 1,501,117 +89% 0.06% $52,809,297
SUSQUEHANNA INTERNATIONAL GROUP, LLP 1.3% 1,423,831 -32% 0.07% $50,090,375
AMERIPRISE FINANCIAL INC 1.2% 1,339,104 -36% 0.01% $47,109,681
BNP PARIBAS FINANCIAL MARKETS 0.88% 992,695 0% 0.02% $34,923,010
UBS Group AG 0.83% 934,925 -30% 0.01% $32,890,662
RAYMOND JAMES FINANCIAL INC 0.81% 921,998 -3.4% 0.01% $32,435,889
GOLDMAN SACHS GROUP INC 0.74% 832,651 +211% 0% $29,292,662
Pictet Asset Management Holding SA 0.67% 752,732 -37% 0.03% $26,481,112
ExodusPoint Capital Management, LP 0.64% 722,199 +254% 0.28% $25,406,961
Artia Global Partners LP 0.64% 719,365 +392% 4.1% $25,307,261
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.62% 700,295 +0.37% 0% $24,636,378
BlackBarn Capital Partners LP 0.49% 550,000 +10% 6.9% $19,349,000
JPMORGAN CHASE & CO 0.48% 546,828 -79% 0% $19,237,409
NORTHERN TRUST CORP 0.48% 541,054 -2.9% 0% $19,034,280
Connor, Clark & Lunn Investment Management Ltd. 0.46% 518,796 -4.7% 0.05% $18,251,243

Institutional Holders of Viking Therapeutics, Inc. - COMMON STOCK (VKTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 71,839,104 $2,527,302,429 -$4,915,384 $35.18 413
2025 Q3 71,269,115 $1,872,831,260 -$129,887,705 $26.28 366
2025 Q2 76,160,666 $2,018,412,050 +$15,581,298 $26.50 386
2025 Q1 76,178,049 $1,840,349,819 -$233,469,532 $24.15 365
2024 Q4 82,015,393 $3,300,204,748 -$139,093,256 $40.24 405
2024 Q3 82,930,091 $5,250,281,341 +$233,179,536 $63.31 418
2024 Q2 80,417,324 $4,262,902,509 -$169,985,696 $53.01 383
2024 Q1 80,009,652 $6,559,940,568 +$370,099,401 $82.00 365
2023 Q4 76,419,206 $1,422,250,248 +$18,477,372 $18.61 193
2023 Q3 77,149,919 $854,043,342 +$8,950,047 $11.07 176
2023 Q2 74,791,312 $1,212,232,718 +$127,119,937 $16.21 192
2023 Q1 66,472,048 $1,107,025,988 +$548,273,938 $16.65 183
2022 Q4 34,003,932 $319,613,212 +$76,425,883 $9.40 126
2022 Q3 26,578,143 $72,293,762 -$1,008,538 $2.72 95
2022 Q2 26,701,115 $77,182,300 -$11,574,558 $2.89 97
2022 Q1 31,036,457 $93,177,398 -$16,601,086 $3.00 131
2021 Q4 36,199,999 $166,471,159 -$8,903,915 $4.60 133
2021 Q3 37,764,404 $237,662,655 -$338,194 $6.28 125
2021 Q2 37,867,341 $226,858,479 -$19,626,288 $5.99 133
2021 Q1 41,005,365 $259,319,860 +$20,962,700 $6.32 137
2020 Q4 37,734,744 $212,602,882 -$11,096,629 $5.63 136
2020 Q3 39,564,196 $230,268,043 -$4,355,775 $5.82 139
2020 Q2 40,230,477 $290,007,852 +$8,150,488 $7.21 133
2020 Q1 39,356,943 $184,161,493 -$8,373,431 $4.68 130
2019 Q4 39,771,461 $318,974,059 -$5,272,426 $8.02 134
2019 Q3 40,703,230 $280,039,135 -$33,395,341 $6.88 139
2019 Q2 45,087,675 $374,231,879 -$7,341,449 $8.30 150
2019 Q1 45,718,634 $454,329,676 -$4,966,661 $9.94 158
2018 Q4 46,936,233 $359,030,721 -$11,223,062 $7.65 159
2018 Q3 43,213,947 $752,787,195 +$280,535,030 $17.42 146
2018 Q2 31,601,829 $299,901,220 +$126,057,321 $9.49 115
2018 Q1 20,905,622 $91,354,000 +$50,569,356 $4.37 62
2017 Q4 9,329,591 $37,876,000 +$30,074,098 $4.06 32
2017 Q3 2,021,286 $3,851,000 +$1,491,357 $1.91 16
2017 Q2 1,568,425 $1,692,000 +$856,257 $1.08 11
2017 Q1 769,601 $1,124,000 +$226,915 $1.46 10
2016 Q4 636,030 $757,000 -$869,302 $1.19 11
2016 Q3 1,209,905 $1,701,000 +$495,636 $1.41 13
2016 Q2 860,090 $1,083,000 +$1,026,020 $1.26 12
2016 Q1 44,443 $65,000 -$25,998 $1.53 6
2015 Q4 41,278 $140,000 -$14,614 $3.36 5
2015 Q3 43,175 $252,000 -$77,596 $5.83 6
2015 Q2 54,005 $384,000 +$384,000 $7.10 5